Drug disposition and drug-drug interactions: Importance of first-pass metabolism in gut and liver

Enzyme- and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges

Volumn , Issue , 2010, Pages 415-435

  Yeung, Catherine K ^a   Zhao, Ping ^b   Shen, Danny D ^a   Thummel, Kenneth E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955278406     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-0840-7_17     Document Type: Chapter

References (82)

1. Allen RD, Hunnisett AG and Morris PJ (1985) Cyclosporin and rifampicin in renal transplantation. Lancet 1:980.
2. Ayanian JZ, Fuchs CS and Stone RM (1988) Lovastatin and rhabdomyolysis. Ann Intern Med 109:682-683.
3. Basu NK, Kole L, Kubota S and Owens IS (2004) Human UDP- glucuronosyltransferases show atypical metabolism of mycophenolic acid and inhibition by curcumin. Drug Metab Dispos 32:768-773.
4. Bernard O and Guillemette C (2004) The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos 32:775-778.
5. Biesenbach G, Janko O, Stuby U and Zazgornik J (1996) Myoglobinuric renal failure due to longstanding lovastatin therapy in a patient with pre-existing chronic renal insufficiency. Nephrol Dial Transplant 11:2059-2060.
6. Bullingham RE, Nicholls AJ and Kamm BR (1998) Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34:429-455.
7. Cassidy MJ, Van Zyl-Smit R, Pascoe MD, Swanepoel CR and Jacobson JE (1985) Effect of rifampicin on cyclosporin A blood levels in a renal transplant recipient. Nephron 41:207-208.
8. Chandwani A and Shuter J (2008) Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag 4:1023-1033.
9. Chien JY, Lucksiri A, Ernest CS, 2nd, Gorski JC, Wrighton SA and Hall SD (2006) Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab Dispos 34:1208-1219.
10. Coles BF, Chen G, Kadlubar FF and Radominska-Pandya A (2002) Interindividual variation and organ-specific patterns of glutathione S-transferase alpha, mu, and pi expression in gastrointestinal tract mucosa of normal individuals. Arch Biochem Biophys 403:270-276.
11. Corpier CL, Jones PH, Suki WN, Lederer ED, Quinones MA, Schmidt SW and Young JB (1988) Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. JAMA 260:239-241.
12. De Lannoy IA and Pang KS (1987) Effect of diffusional barriers on drug and metabolite kinetics. Drug Metab Dispos 15:51-58.
13. Dresser GK, Spence JD and Bailey DG (2000) Pharmacokinetic- pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:41-57.
14. Eagling VA, Back DJ and Barry MG (1997) Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44:190-194.
15. Edwards DJ, Bellevue FH, 3rd and Woster PM (1996) Identification of 6', 7'-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos 24:1287-1290.
16. Faucette SR, Zhang TC, Moore R, Sueyoshi T, Omiecinski CJ, Le Cluyse EL, Negishi M and Wang H (2007) Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 320:72-80.
17. Fleishaker JC, Pearson PG, Wienkers LC, Pearson LK and Peters GR (1996) Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability. J Pharmacol Exp Ther 277:991-998.
18. Fromm MF, Busse D, Kroemer HK and Eichelbaum M (1996) Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 24:796-801.
19. Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B and Hall SD (2003) The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 74:275-287.
20. Greenblatt DJ, Von Moltke LL, Harmatz JS, Chen G, Weemhoff JL, Jen C, Kelley CJ, Le Duc BW and Zinny MA (2003) Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clin Pharmacol Ther 74:121-129.
21. Gutmann H, Fricker G, Drewe J, Toeroek M and Miller DS (1999) Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 56:383-389.
22. Gwilt PR, Comer S, Chaturvedi PR and Waters DH (1988) The influence of diffusional barriers on presystemic gut elimination. Drug Metab Dispos 16:521-526.
23. Her C, Szumlanski C, Aksoy IA and Weinshilboum RM (1996) Human jejunal estrogen sulfotransferase and dehydroepiandrosterone sulfotransferase: immunochemical characterization of individual variation. Drug Metab Dispos 24:1328-1335.
24. Hickman D, Pope J, Patil SD, Fakis G, Smelt V, Stanley LA, Payton M, Unadkat JD and Sim E (1998) Expression of arylamine N-acetyltransferase in human intestine. Gut 42:402-409.
25. Hino I, Akama H, Furuya T, Ueda H, Taniguchi A, Hara M and Kashiwazaki S (1996) Pravastatininduced rhabdomyolysis in a patient with mixed connective tissue disease. Arthritis Rheum 39:1259-1260.
26. Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE and Heidemann H (1996) The nifedipinerifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab Dispos 24:1121-1123.
27. Hönig PK, Wortham DC, Zamani K, Conner DP, Mullin JC and Cantilena LR (1993) Terfenadineketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 269:1513-1518.
28. Keogh A, Spratt P, McCosker C, Macdonald P, Mundy J and Kaan A (1995) Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med 333:628-633.
29. Kiang TK, Ensom MH and Chang TK (2005) UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106:97-132.
30. Kim YH, Yoon YR, Kim YW, Shin JG and Cha IJ (1998) Effects of rifampin on cyclosporine disposition in kidney recipients with tuberculosis. Transplant Proc 30:3570-3572.
31. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM and Watkins PB (1994) CYP3A gene expression in human gut epithelium. Pharmacogenetics 4:247-259.
32. Kupferschmidt HH, Fattinger KE, Ha HR, Follath F and Krahenbuhl S (1998) Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 45:355-359.
33. Kuypers DR, Verleden G, Naesens M and Vanrenterghem Y (2005) Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphateglucuronosyltransferase. Clin Pharmacol Ther 78:81-88.
34. Lilja JJ, Neuvonen M and Neuvonen PJ (2004) Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol 58:56-60.
35. Lin YS, Lockwood GF, Graham MA, Brian WR, Loi CM, Dobrinska MR, Shen DD, Watkins PB, Wilkinson GR, Kharasch ED and Thummel KE (2001) In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics 11:781-791.
36. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W and Watkins PB (1997) Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 99:2545-2553.
37. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA and Watkins PB (1994) Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 22:947-955.
38. Lundahl J, Regardh CG, Edgar B and Johnsson G (1997) Effects of grapefruit juice ingestion-pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol 52:139-145.
39. Mahmood I and Sahajwalla C (1999) Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clin Pharmacokinet 36:277-287.
40. Masica AL, Mayo G and Wilkinson GR (2004) In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clin Pharmacol Ther 76:341-349.
41. Merry C, Barry MG, Mulcahy F, Ryan M, Heavey J, Tjia JF, Gibbons SE, Breckenridge AM and Back DJ (1997) Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. Aids 11:F29-F33.
42. Mizuma T (2002) Kinetic impact of presystemic intestinal metabolism on drug absorption: experiment and data analysis for the prediction of in vivo absorption from in vitro data. Drug Metab Pharmacokinet 17:496-506.
43. Mizuma T, Tsuji A and Hayashi M (2004) Does the well-stirred model assess the intestinal firstpass effect well?. J Pharm Pharmacol 56:1597-1599.
44. Modry DL, Stinson EB, Oyer PE, Jamieson SW, Baldwin JC and Shumway NE (1985) Acute rejection and massive cyclosporine requirements in heart transplant recipients treated with rifampin. Transplantation 39:313-314.
45. Mouly S, Lown KS, Kornhauser D, Joseph JL, Fiske WD, Benedek IH and Watkins PB (2002) Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 72:1-9.
46. Nakamura A, Nakajima M, Yamanaka H, Fujiwara R and Yokoi T (2008) Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 36:1461-1464.
47. Niemi M, Backman JT, Fromm MF, Neuvonen PJ and Kivisto KT (2003) Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 42:819-850.
48. Offermann G, Keller F and Molzahn M (1985) Low cyclosporin A blood levels and acute graft rejection in a renal transplant recipient during rifampin treatment. Am J Nephrol 5:385-387.
49. Ohno S and Nakajin S (2009) Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32-40.
50. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE and Zeldin DC (2006a) The human intestinal cytochrome P450 "pie". Drug Metab Dispos 34:880-886.
51. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552-1562.
52. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS and Thummel KE (1996) First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60:14-24.
53. Paine MF, Widmer WW, Hart HL, Pusek SN, Beavers KL, Criss AB, Brown SS, Thomas BF and Watkins PB (2006b) A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am J Clin Nutr 83:1097-1105.
54. Pang KS (2003) Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). Drug Metab Dispos 31:1507-1519.
55. Paris DG, Parente TF, Bruschetta HR, Guzman E and Niarchos AP (1994) Torsades de pointes induced by erythromycin and terfenadine. Am J Emerg Med 12:636-638.
56. Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J and Raunio H (2008) Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 82:667-715.
57. Petty KJ and Vega JM (2008) Drug-drug interactions: marketing perspectives, in Drug-drug Interactions (Rodrigues AD ed) pp 711-713, Informa Healthcare, New York.
58. Picard N, Ratanasavanh D, Premaud A, Le Meur Y and Marquet P (2005) Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 33:139-146.
59. Radominska-Pandya A, Little JM, Pandya JT, Tephly TR, King CD, Barone GW and Raufman JP (1998) UDP-glucuronosyltransferases in human intestinal mucosa. Biochim Biophys Acta 1394:199-208.
60. Rowland M and Matin SB (1973) Kinetics of drug-drug interactions. J Pharmacokinet Biopharm 1:553-567.
61. Rowland M and Tozer TN (1995) Clinical Pharmacokinetics: Concepts and Applications. Lippincott, Philadelphia.
62. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF and Watkins PB (1997) Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 25:1228-1233.
63. Shen DD, Madani S, Banfield C and Clement RP (2000) H1-receptor antagonists, in Metabolic Drug Interactions (Levy RH, Thummel KE, Trager WF, Hansten PD and Eichelbaum M eds) pp 435-455, Lippincott Williams & Wilkins, Philadelphia.
64. Shipkova M, Armstrong VW, Wieland E, Niedmann PD, Schutz E, Brenner-Weiss G, Voihsel M, Braun F and Oellerich M (1999) Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol 126:1075-1082.
65. Strassburg CP, Kneip S, Topp J, Obermayer-Straub P, Barut A, Tukey RH and Manns MP (2000) Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem 275:36164-36171.
66. Strassburg CP, Nguyen N, Manns MP and Tukey RH (1999) UDP-glucuronosyltransferase activity in human liver and colon. Gastroenterology 116:149-160.
67. Strolin Benedetti M and Bani M (1999) Metabolism-based drug interactions involving oral azole antifungals in humans. Drug Metab Rev 31:665-717.
68. Tam D, Sun H and Pang KS (2003) Influence of P-glycoprotein, transfer clearances, and drug binding on intestinal metabolism in Caco-2 cell monolayers or membrane preparations: a theoretical analysis. Drug Metab Dispos 31:1214-1226.
69. Thummel KE, Kunze KL and Shen DD (1997) Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev 27:99-127.
70. Thummel KE, Shen DD and Isoherranen N (2008) Role of the gut mucosa in metabolically based drug-drug interactions, in Drug-drug Interactions (Rodrigues AD ed) pp 472-473, Informa Healthcare, New York.
71. Thummel KE and Wilkinson GR (1998) In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430.
72. Tukey RH and Strassburg CP (2001) Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol 59:405-414.
73. Vandevelde C, Chang A, Andrews D, Riggs W and Jewesson P (1991) Rifampin and ansamycin interactions with cyclosporine after renal transplantation. Pharmacotherapy 11:88-89.
74. Veronese ML, Gillen LP, Burke JP, Dorval EP, Hauck WW, Pequignot E, Waldman SA and Greenberg HE (2003) Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharmacol 43:831-839.
75. Von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M and Kivisto KT (2004) Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 75:172-183.
76. Von Richter O, Greiner B, Fromm MF, Fraser R, Omari T, Barclay ML, Dent J, Somogyi AA and Eichelbaum M (2001) Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clin Pharmacol Ther 70:217-227.
77. Woosley RL, Chen Y, Freiman JP and Gillis RA (1993) Mechanism of the cardiotoxic actions of terfenadine. JAMA 269:1532-1536.
78. Yang J, Jamei M, Yeo KR, Tucker GT and Rostami-Hodjegan A (2007) Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676-684.
79. Yang J, Kjellsson M, Rostami-Hodjegan A and Tucker GT (2003) The effects of dose staggering on metabolic drug-drug interactions. Eur J Pharm Sci 20:223-232.
80. Zhang QY, Dunbar D, Ostrowska A, Zeisloft S, Yang J and Kaminsky LS (1999) Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 27:804-809.
81. Zhang X, Jones DR and Hall SD (2009) Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition. Drug Metab Dispos 37:150-160.
82. Zhou C, Tabb MM, Sadatrafiei A, Grun F and Blumberg B (2004) Tocotrienols activate the steroid and xenobiotic receptor, SXR, and selectively regulate expression of its target genes. Drug Metab Dispos 32:1075-1082.